(firstQuint)ESBA105 in Patients With Severe Dry Eye.

 Following Run-In, patients qualifying for treatment were randomized 2:1 to receive ESBA105 (experimental group) or Vehicle (control group) for 4 weeks.

 Patients not qualifying for treatment (based on global VAS discomfort score), were discontinued from the study.

.

 ESBA105 in Patients With Severe Dry Eye@highlight

The purpose of this study was to evaluate the efficacy of ESBA105 over vehicle in reducing the ocular symptoms of dry eye disease, as measured by a mean global Visual Analog Scale (VAS) discomfort score.

